Abstract: An anode structure comprising a ruthenium catalyst is disclosed. The catalyst consists essentially of ruthenium deposited on a conducting support wherein the ruthenium is in metallic form or in a form that is readily reducible to the metallic form at temperatures of 25° C. to 150° C. The anode structure is particularly of use in proton exchange membrane fuel cell to prevent poisoning of the electrocatalyst by impurities in the fuel stream to the anode.

Abstract: Copolymerization of Ni(H) or Co(II) acenaphthene diimine complexes containing olefinic substituents on aryl groups in the presence of a free radical initiator results in polymerized late transition metal catalysts which can be used for olefin polymerization or oligomerization. These catalysts have high catalyst activity for olefin polymerization or oligomerization.

Abstract: A catalyst and sorbent is disclosed which comprises pellets with an absorbent core and a protective shell with a catalyst in the shell. Such material is especially well suited for steam reforming of hydrocarbons to produce hydrogen since a reforming catalyst can be incorporated in the shell and a sorbent for the by-product carbon dioxide can be used for the core. It is also well suited for producing hydrogen from carbon monoxide by means of the water gas shift reaction. The shell can be made sufficiently strong and durable for moving bed applications as well as fixed bed applications.

Abstract: A method is provided for forming a highly active Fischer-Tropsch catalyst using boehmite having a particular crystallite size. In this method, a support material comprising boehmite is contacted with a catalytic metal-containing compound to form a catalyst precursor. The boehmite is selected to have an average crystallite size in the range of from about 6 nanometers (nm) to about 30 nm. An alternate embodiment uses a mixture of boehmites with various average crystallite sizes in the range of from about 4 nm to about 30 nm, differing by at least by 1 nm. Subsequently, the catalyst precursor is calcined to convert the boehmite to a stabilized aluminum oxide structure, thereby forming a catalyst support having a good attrition resistance and a relatively high hydrothermal stability.

Abstract: There are disclosed imaging members wherein a chemical compound in a crystalline form is converted, at least partially, and preferably substantially completely or completely, to a liquid in the amorphous form, the liquid having intrinsically a different color from the crystalline form. Also described are imaging methods utilizing the imaging members. The conversion of the compound from the crystalline form to the liquid form can be effected by the application of thermal energy or by other imaging techniques.

Abstract: The present invention provides a heat-sensitive recording material including a support having disposed thereon a heat-sensitive recording layer containing microcapsules in which an electron-donating dye precursor is encapsulated and outside which an electron-accepting compound is present, the electron-donating dye precursor being capable of reacting with the electron-accepting compound to develop color, wherein the microcapsules include at least two kinds of microcapsules having mutually different volume average particle diameters or different glass transition temperatures. A difference between each of the glass transition temperatures of the at least two microcapsules having different glass transition temperatures is preferably in a range from 20° C. to 70° C. According to the invention, a heat-sensitive recording material, which is superior in the reproduction of the gradation of an image and enables recording at high density, is obtained.

Abstract: By applying a compound selected from jasmonic acid represented by the following general formula (I) or 2-substituted form of jasmonic acid or derivatives thereof or salts thereof, the pharmacological action of a pesticide such as a microbicide or a herbicide applied to the plant is enhanced. (wherein R1 is an alkyl group or an alkenyl group, and R2 is a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group or a hydroxyalkyl group).

Abstract: A process for preparing novel 1,3-selanazolin derivatives represented by chemical formula 1 at high yield.

Abstract: An additive that increases the density of fluids containing a sized barite weighting agent. The wellbore fluid has rheological properties comparable to a conventional wellbore fluids but does not exhibit problems with sag and resulting variations in density. An illustrative embodiment is directed to a method for making the sized barite weighting agent and a method for using such sized barite weighting agent in a wellbore fluid. In one preferred embodiment the sized barite weighting agent has a particle diameter between 4 ?m to 15 ?m In another preferred embodiment, the additive has a D50 (by weight) of approximately 1 ?m to 6 ?m. In another preferred embodiment the additive has a D90 (by weight) of approximately 4 ?m to 8 ?m. The additive may be used in any wellbore fluid such as drilling, cementing, completion, packing, work-over (repairing), stimulation, well killing, and spacer fluid.

Abstract: The present invention intends to provide a slide member with increasing an abrasion resistance and an adherence, a friction coefficient is further decreased. A part of the base member surface of the slide member is provided with a streak so that a surface roughness thereof by a ten-point height of roughness profile is 8 to 18 ?mRz. A dry coat lubricant has polyamideimide resin, at least one kind of a layer improve agent selected from epoxysilane and epoxy resin, and at least one kind of hard particles selected from a silicon nitride and an alumina. Such construction can not only increase the abrasion resistance and the adherence of the slide member, but can decrease friction coefficient of the slide member.

Abstract: According to the invention, a self contained vibration resistant bearing is provided. The bearing is coated with a film formed from a rust preventive oil having an extreme-pressure additive content of 0.5 to 10% by weight. Desirably the extreme-pressure additive is an organometallic compound, an organofatty acid compound, organofatty acid derivative, an organophosphoric acid compound or a combination of two(2) or more of such compounds. When a rust preventive film that contains an extreme-pressure additive is formed all over bearing components during the assembling process, the bearing components are fully protected even from sudden vibrations from transportation.

Abstract: The present invention describes an improved lubricant composition comprising a particularly effective combination of components comprising ashless antiwear and rust inhibitor additives with an antioxidant liquid mixture formed by reacting an olefin with a mixture of diphenylamines and phenothiozines.

Abstract: A lubricant composition for use in a rotary vane compressor has a base oil component that comprises an alkylbenzene as a major component thereof and a polyol ester as a minor component thereof. In particular, the base oil component comprises at least 55% by weight of alkylbenzene and at most 45% by weight of a polyol ester, more preferably between 55% and 75% by weight of alkylbenzene and between 45% and 25% by weight of polyol ester and, especially, between 60% and 75% by weight of alkyl benzene and between 45% and 25% by weight of polyol ester.

Abstract: The present invention relates to a composition for washing keratinous substances, preferably keratinous fibers, comprising, in a cosmetically acceptable aqueous medium, at least one anionic or nonionic, amphiphilic linear block copolymer comprising at least one hydrophobic block and at least one hydrophilic block, with the exception of block copolymers of ethylene oxide and of propylene oxide, block copolymers comprising urethane units and block copolymers comprising siloxane units, at least one nonvolatile silicone, and at least one anionic surface-active agent in combination with at least one nonionic and/or amphoteric surface-active agent, and to the use of such a composition for washing keratinous substances.

Abstract: An emulsifier mixture for use in a wax-based opacifier composition is comprised of: (a) an alkyl and/or alkenyl oligoglycoside; (b) a fatty acid partial glyceride and optionally (c) at least one amphoteric surfactant, with the proviso that the ratio by weight of (a) and optionally (c) to (b) is between 6:1 and 3:1 and wherein the composition is free from anionic surfactants.

Abstract: A personal care product is provided which includes a package filed with a personal care composition and instructions printed on or associated with the package indicating topical use of the composition on skin for purposes of controlling the signs of aging. The composition includes a quaternary ammonium compound selected from (a) salts of hydroxypropyltri(C1–C3 alkyl)ammonium mono-substituted mono-saccharide; (b) salts of hydroxypropyltri(C1–C3 alkyl)ammonium mono-substituted polyols, the salts having a cation of an average molecular weight no higher than about 450 and the salt having a Tg no higher than about 10° C.; (c) dihydroxypropyltri(C1–C3 alkyl)ammonium salts; (d) chlorohydroxypropyltri(C1–C3 alkyl)ammonium salts; and (e) mixtures thereof.

Abstract: An object of the present invention is to provide washing liquid for semiconductor substrate capable of removing grinding grains of silica, alumina or the like in a polishing agent and polishing trashes of copper, and capable of leaving little organic substance due to an additive used for preventing corrosion of copper on the surface of a copper wiring after washing, while corrosion of copper is suppressed, and a method of producing a semiconductor device using this washing liquid. The object is achieved by washing liquid for a semiconductor substrate having a copper wiring, comprising a basic compound and at least one selected from the group consisting of sugar alcohols and saccharides.

Abstract: A water-in-oil emulsion composition is disclosed. The composition contains (A) a solvent, (B) water, and (C) a surfactant. This composition is suitable for removing non-aqueous coatings such as paints and the like as well as waxes and greases from substrates.

Abstract: A cleansing processing agent that is able to remove harmful substances contained in a variety of waste materials and a cleansing method are disclosed. Specifically, there is disclosed a cleansing processing agent containing a polymer having at least one of styrene or conjugate diene and acrylonitrile as constituent unit and into which are introduced ionic groups. This cleansing processing agent is contacted with a material for processing containing harmful substances contained in the material for processing for removing the harmful substances. The waste plastics can be used effectively, while a modified product obtained on chemical modification of the plastics is useful for suppressing environmental destruction caused by leakage of the harmful substances contained in the waste materials.

Abstract: The sensory properties of the diastereomeric enantiomer pairs and of the pure enantiomers of the compound 2-methyl-4-phenyl-1,3-dioxolane are described. The cis compounds (2R,4S)-2-methyl-4-phenyl-1,3-dioxolane and (2S,4R)-2-methyl-4-phenyl-1,3-dioxolane are the most sensorially valuable. These enantiomers and mixtures thereof are particularly suitable for use as a sensorially active substance, for example as a fragrance.

Abstract: 4,8-dimethyl-3,7-nonadien-2-one has aromatizing properties and increases the extendibility and intensity of the aroma when used in an aroma composition.

Abstract: A nuclear delivery construct comprises (i) protein H or a fragment or derivative thereof that is capable of being targeted to the nucleus of a eukaryotic cell; and associated therewith (ii) one or more other components whose targeting to the nucleus of the eukaryotic cell is desired.

Abstract: The present invention is directed to compositions and methods for selective induction of apoptosis in cancer cells, particularly malignant cancer cells, by delivery of a IL-1? propiece polypeptide (e.g., a native IL-1? propiece polypeptide, including IL-1? propiece polypeptide variant) to a cancer cell.

Abstract: The present invention provides novel isolated CRF2-12 polynucleotides and polypeptides encoded by the CRF2-12 polynucleotides. Also provided are the antibodies that immunospecifically bind to a CRF2-12 polypeptide or any derivative (including fusion derivative), variant, mutant or fragment of the CRF2-12 polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the CRF2-12 polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.

Abstract: The present invention provides compositions that enhance or inhibit the interactions of galectin-8 and galectin-8-like proteins with other extracellular matrix proteins or cell surface receptors, and methods for the use thereof as physiological modulators of cell adhesion and in treatment of tumors, both in vivo or ex vivo. It further provides compositions and methods for modulating the expression of galectin-8, and galectin-8-like proteins, particularly to novel antisense oligonucleotides.

Abstract: The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the large intestine. In particular, it has now been demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue of large intestine. Thus, the invention provides methods of proliferating the large intestine in a subject in need thereof. Further, the methods of the invention are useful to treat or prevent inflammatory conditions of the large intestine, including inflammatory bowel diseases.

Abstract: The present invention provides improved methods, kits, and pharmaceutical compositions for treating and preventing damage to mucosal tissue by administering an effective amount of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII analogues, AII fragments or analogues thereof or AII AT2 type 2 receptor agonists to the subject.

Abstract: A method for the treatment of inflammatory bowel disease (IBD) is disclosed. The method comprises administration of an antibody, polypeptide or other molecule recognizing VLA-4, a surface molecule expressed on most types of white blood cells and involved in leukocyte adhesion to endothelium and other tissus in the gut.

Abstract: A dipeptide or tripeptide carrier system for active agent delivery to cells has an N-terminus natural amino acid and an active agent covalently bonded to a side chain of one of the remaining amino acid bases. The system is amenable to formulation as an oral administrant. The active agent being a therapeutic, a fluorescent dye, or contrast agent where the active agent has a molecular weight of less than 500 atomic mass units. An optional linker is provided intermediate between the active agent and the linking side chain.

Abstract: The present invention relates to various methods of genetic immunization for the purpose of providing antigen-specific immunity in a mammalian host, including a human host. The invention is based on the ability to direct particulate polynucleotides which express an antigenic protein or protein fragment to the cytoplasm of host target cells, such as antigen presenting cells. A directed delivery of such particulate polynucleotides to the cytoplasm of antigen presenting cells will stimulate antigen-specific CTL production, thus promoting destruction of affected cells such as neoplastic cells and virally infected cells.

Abstract: The present invention is directed to fusion proteins that can be used to assay gene transfer and expression both in vitro and in vivo. The fusion proteins contain a reporter protein, e.g. a somatostatin receptor, fused to a second protein, which may be a protein fusion tag. Alternatively, a fusion protein may be fused to a leader sequence. A leader sequence may localize an expressed protein, e.g. localize a fusion protein to the cell membrane. The invention includes nucleic acids encoding the fusion proteins and methods of assaying for gene expression.

Abstract: The present invention relates to a method, nucleic acid and amino acid sequences to sensitizing human or animal cells to be killed by chemical entities or irradiation. Particularly, the present invention describes nucleic acid and amino acid sequences pertaining to the group of PME factors, that are target to sensitizing the cells before treatment with killing elements.

Abstract: The invention relates to methods for transdifferentiation of body tissues which can be used to generate specific cell types needed for regenerating a lens in the mammalian eye, following loss or removal of the original lens.

Abstract: Nucleic acid molecules are described encoding a starch granule-bound protein as well as methods and recombinant DNA molecules for the production of transgenic plant cells and plants synthesizing a modified starch with modified viscosity properties and a modified phosphate content. Moreover, the plant cells and plants resulting from those methods as well as the starch obtainable therefrom are described.

Abstract: The present invention provides protonated compounds having antimicrobial activity. The invention also provides antimicrobial compositions comprising protonated compounds of the invention. The protonated compounds of the invention provide efficacious antimicrobial activity against resistant strains of bacteria and opportunistic fungi.

Abstract: This invention relates to a method of treating a patient suffering from ionizing radiation exposure, or of treating a patient about to undergo ionizing radiation therapy. The method includes administering to a patient in need of treatment an effective amount of a thiol or reducible disulfide compound according to the formula set forth in the specification.

Abstract: One embodiment of the invention relates to compounds of the formula I: in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification. Other embodiments of the invention relate to physiologically acceptable salts of the compounds of formula 1, to processes for their preparation and to medicaments comprising these compounds. The compounds of the invention are suitable for use, for example, as hypolipidemics.

Abstract: One embodiment of the invention relates to compounds of the formula I, in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification. Other embodiments of the invention relate to physiologically acceptable salts of compounds of formula I, to processes for their preparation and to medicaments comprising these compounds. The compounds of the invention are suitable for use, for example, as hypolipidemics.

Abstract: Compounds according to general formulae (1 and 2), wherein G1 is an azepine derivative and G2 is a group according to general formulae (9–11) are new. Compounds according to the invention are vasopressin V2 receptor agonists.

Abstract: The invention encompasses a series cyclic bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

Abstract: Process for the synthesis of ivabradine of formula (I): addition salts with a pharmaceutically acceptable acid and hydrates thereof. ? crystalline form of ivabradine hydrochloride. Medicinal products containing the a crystalline form of ivabradine hydrochloride, which are useful as bradycardics.

Abstract: The invention provides compounds of Formula I: wherein Azabicyclo is where the variables have the definitions discussed herein. These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals to treat a disease or condition in which ?7 is known to be involved.

Abstract: An aryl-substituted alicyclic compound of the formula (I): wherein U is 1,4,5,6-tetrahydropyrimidin-2-yl, etc., A is phenylene, etc., B is piperidine-1,4-diyl, etc., Z is —CONH—, etc., R3 is hydrogen, etc., R5 is hydrogen, aryl, etc., R6 is a mono-substituted amino (e,g., benzyloxycarbonylamino), R7 is hydrogen, etc., and a process for preparation thereof, and a pharmaceutical composition containing the same. The compound of the present invention has a high selectivity for ?v?3 integrin, and exhibits a potent inhibitory activity thereto, and hence, it is useful as a preventive or/and a therapeutic agent for a disease in which ?v?3 integrin is involved.

Abstract: The present invention relates to new derivatives of sulphonamides, with the general formula (I), as well as to their physiologically acceptable salts, the processes for their preparation, their application as medicaments in human and/or veterinary therapy and the pharmaceutical compositions that contain them

Abstract: Fatty acid amide hydrolase inhibitors of the Formula: are provided wherein X is NH, CH2, O, or S; Q is O or S; Z is O or N; R is an aromatic moiety selected from the group consisting of substituted or unsubstituted aryl; substituted or unsubstituted biphenylyl, substituted or unsubstituted naphthyl, and substituted or unsubstituted phenyl; substituted or unsubstituted terphenylyl; substituted or unsubstituted cycloalkyl, heteroaryl, or alkyl; and R1 and R2 are independently selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, and substituted or unsubstituted phenyl, substituted or unsubstituted biphenylyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; with the proviso that if Z is O, one of R1 and R2 is absent, and that if Z is N, optionally R1 and R2 may optionally be taken together to form a substituted or unsubstituted N-heterocycle or substituted or unsubstituted heteroaryl with the N atom to which they

Abstract: The present invention provides benzamide inhibitors of the P2X7 receptor of the formula: wherein R1–R3 are as defined herein. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

Abstract: A class of imidazo[1,2b][1,2,4]triazine derivatives, substituted at the 7-position by an optionally substituted five-membered or six-membered heteroaromatic ring, being selective ligands for GABAA receptors, in particular having good affinity for the ?2 and/or ?3 and/or ?5 subunit thereof, are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders.

Abstract: Novel substituted carboxylic acid derivatives which bind as ligands to human peroxisome proliferator activated receptor (PPAR) to activate the receptor and thereby exhibit potent effects of decreasing neutral fat, cholesterol, and blood sugar; and a processes for preparing the derivatives.

Abstract: The present invention relates to compounds of the formula wherein R1 and R1? are each independently hydrogen or methyl and X is —C(O)N(CH3)— or —N(CH3)C(O)—, and to pharmaceutically acceptable acid addition salts thereof for the treatment of numerous inflammatory conditions, migraine, rheumatoid arthritis, asthma, inflammatory bowel disease, mediation of the emetic reflex, Parkinson's disease, anxiety, depression, psychosis, motion sickness, induced vomiting, pain, headache, migraine, Alzheimer's disease, multiple sclerosis, attenuation of morphine withdrawal, cardiovascular changes, oedema, such as oedema caused by thermal injury, chronic inflammatory diseases such as rheumatoid arthritis, asthma/bronchial hyperreactivity and other respiratory diseases including allergic rhinitis, inflammatory diseases of the gut including ulcerative colitis and Crohn's disease, ocular injury and ocular inflammatory diseases, traumatic brain injury, motion sickness, emesis and psychoimmunologic and psychosomatic disorder

Abstract: The invention provides compounds of the general formula: wherein X is selected from the group consisting of oxygen, sulfur and nitrogen-containing groups selected from azine, oxime, hydrazone, aromatic hydrazone, aliphatic hydrazone, semicarbazone, guanidinyl group, and aliphatic or aromatic imines; Y is selected from the group of halogens; R1 and R2 are independently selected from the group consisting of H, lower alkyl group (of C1 up to C6), lower hydroxyalkyl group (of C1 up to C6), lower O-alkyl group (of C1 up to C6), lower alkylcarbonyl group (of C2 up to C6), lower alkyloxycarbonyl group (of C1 up to C6), haloalkylcarbonyl group (of C1 up to C6), or arylsulfonyl group, and their pharmaceutically acceptable salts. The compounds are useful as active ingredients in pharmaceutical compositions. The invention relates to the use of the said compounds as a medicament, in particular as an antibiotic.